ABSTRACT
Introduction Youth (adolescents and young adults) aged 15-24 years comprise approximately 22% of Ethiopia’s total population and make up 0.73% of HIV cases in urban Ethiopia. However, only 63% of HIV-positive youth are aware of their HIV status. We described the HIV testing behaviors of youth 15-24 years and determined the characteristics of those who were most likely to be tested for HIV within the past year.
Methods Using data from the 2017-2018 Ethiopia Population-based HIV Impact Assessment, we provide survey-weighted estimates and prevalence risk ratios for engagement in HIV testing in the 12 months preceding the survey. We model the likelihood of HIV testing one year or more before the survey compared to never testing, using a multinomial logistic regression model.
Results Among HIV-negative and unaware HIV-positive youth 15-24 years old (N=7,508), 21.8% [95% Confidence Interval (CI): 20.4-23.3%] reported testing for HIV in the last 12 months. Female youth [Prevalence Ratio (PR)=1.6, 95% CI: 1.4-1.8], those aged 20-24 years (PR=2.6, 95% CI:2.3-2.9), and those ever married (PR=2.8, 95% CI: 2.5-3.1) were more likely to have tested for HIV within the last year. Adjusting for select demographic characteristics, sex with a non-spousal or non-live-in partner [Relative Risk (RR)=0.3, 95% CI:0.1-0.8] among males did not increase their likelihood to test for HIV in the prior 12 months. Female youth engaged in antenatal care (RR=3.0, 95% CI: 1.7-5.3) were more likely to test for HIV in the past year.
Conclusion The Ethiopian HIV case finding strategy may consider approaches for reaching untested youth, with a specific focus on adolescent males. This is critical towards achieving the UNAIDS HIV testing goal of 95% of all individuals living with HIV aware of their status by 2030.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This publication has been supported by the President?s Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (CDC) under the terms of cooperative agreement award # 1U2GGH001226. The findings and conclusions in this publication are those of the author(s) and do not necessarily represent the official position of the funding agencies.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of the Ethiopia Public Health Institute gave ethical approval for this work. IRB of Columbia University Medical Center gave ethical approval for this work. IRB of The Centers for Disease Control and Prevention in Atlanta and Ethiopia gave ethical approval for this work. IRB of Westat gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Description of Ethical Clearance: Human Subjects Research, CDC engaged: This study was reviewed and approved by the CDC Institutional Review Board
Disclaimer: The findings and conclusions in this publication are those of the author(s) and do not necessarily represent the official position of the funding agencies.
This publication has been supported by the President’s Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (CDC) under the terms of cooperative agreement award # 1U2GGH001226.
Data Availability
The 2017-2018 EPHIA public release datasets and files are available at the ICAP PHIA website (https://phia-data.icap.columbia.edu/datasets?country_id=12). Survey data use manuals and documentation are available for download. For access to datasets, please register for an account and submit a data request form.